Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Emergent BioSolutions Inc. operates as a global specialty biopharmaceutical company. The Company develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. Emergent BioSolutions also develops and commercializes therapeutics and other specialty products for hospitals and clinics.
Website: emergentbiosolutions.com


  • Bad financial results growth rate -60.6% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (15.8%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 36.4% (LTM)
  • Share price is 447.3% higher than minimum and 44.4% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (4.0x vs 20.6x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.6 mln (-0.131% of cap.)

Key Financials (Download financials)

Ticker: EBS
Share price, USD:  (-3.3%)8.21
year average price 9.98  


year start price 6.33 2025-06-04

min close price 5.63 2025-08-01

max close price 12.84 2025-10-30

current price 8.21 2026-06-03
Common stocks: 50 243 601

Dividend Yield:  0.0%
FCF Yield LTM: 36.4%
EV / LTM EBITDA: 4.0x
EV / Sales: 1.0x
Margin (EBITDA LTM / Revenue): 26.4%

Target EV / EBITDA (hist percentile): 20.6x
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 412
Net Debt ($m): 367
EV (Enterprise Value): 779
EBITDA LTM (млн $): 196
EV / LTM EBITDA: 4.0x
Price to Book: 0.7x
Latest review:

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-14seekingalpha.com

Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-11-06seekingalpha.com

Emergent BioSolutions: Solid Q3, Expecting Better Days To Come

2025-10-31zacks.com

Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out?

2025-10-29seekingalpha.com

Emergent BioSolutions Inc. (EBS) Q3 2025 Earnings Call Transcript

2025-10-29zacks.com

Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates

2025-10-29globenewswire.com

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

2025-10-08globenewswire.com

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

2025-10-01globenewswire.com

Millennium EBS Secures Agreement and Purchase Order from Global IME Bank for ISO 20022 Transformer Solution

2025-09-19globenewswire.com

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

2025-09-15globenewswire.com

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-08-07 2024-11-07 2024-08-07 2024-03-31 2023-12-11 2023-08-09 2023-05-10 2022-11-09
acceptedDate 2025-10-29 17:38:45 2025-08-06 17:50:51 2025-03-03 17:41:27 2024-11-06 17:46:15 2024-08-06 17:37:18 2024-03-30 20:00:00 2024-03-08 16:21:44 2023-12-11 07:24:51 2023-08-08 18:42:41 2023-05-09 17:51:12 2023-12-11 07:17:14 2022-11-08 18:19:51 2022-02-25 16:35:23 2021-02-18 18:52:37
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 231M 141M 1 044M 270M 255M 300M 1 049M 271M 338M 165M 1 118M 240M 1 774M 1 577M
costOfRevenue 92M 80M 668M 0 309M 161M 689M 177M 191M 155M 645M 149M 980M 714M
grossProfit 139M 61M 375M 270M -55M 139M 360M 94M 147M 10M 473M 91M 793M 863M
grossProfitRatio 0.603 0.431 1 -0.214 0.464 0.346 0.436 0.061 0.381
researchAndDevelopmentExpenses 14M 13M 71M 14M 27M 15M 111M 15M 26M 41M 188M 39M 235M 238M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 39M 44M 299M 77M 77M 85M 357M 86M 91M 101M 340M 80M 349M 304M
otherExpenses 11M 3M 115M 139M -3M -3M 618M -3M -4M 17M 115M 14M -132M -117M
operatingExpenses 63M 59M 484M 229M 105M 100M 1 086M 118M 134M 158M 643M 133M 452M 425M
costAndExpenses 155M 139M 1 152M 229M 414M 261M 1 776M 294M 324M 313M 1 288M 282M 1 432M 1 139M
interestIncome 0 0 0 0 0 0 0 0 29M 0 0 0 0 0
interestExpense 15M 15M 71M 8M 24M 24M 88M 20M 29M 18M 37M 9M 35M 31M
depreciationAndAmortization 23M 23M 106M 26M 29M 29M 121M 16M 33M 40M 125M 19M 118M 110M
ebitda 96M 24M 53M 65M -217M 69M -47M -11M 43M -109M 16M -23M 504M 609M
ebitdaratio 0.416 0.167 0.239 -0.509 0.228 -0.041 0.128 -0.658 -0.096
operatingIncome 77M 2M -109M 65M -159M 40M -726M -242M -293M -148M -170M -42M 341M 439M
operatingIncomeRatio 0.331 0.011 0.239 -0.625 0.132 -0.895 -0.867 -0.897 -0.175
totalOtherIncomeExpensesNet -19M -18M -34M 78M -111M -28M -5M -222M -235M -13M -49M -22M -38M -27M
incomeBeforeTax 58M -17M -143M 142M -270M 12M -731M -266M -250M -161M -219M -64M 303M 412M
incomeBeforeTaxRatio 0.249 -0.119 0.528 -1.059 0.04 -0.983 -0.74 -0.976 -0.266
incomeTaxExpense 6M -5M 48M 28M 13M 3M 29M 16M 11M 22M -7M 12M 84M 106M
netIncome 51M -12M -191M 115M -283M 9M -761M -266M -261M -183M -212M -76M 220M 306M
netIncomeRatio 0.222 -0.085 0.426 -1.112 0.03 -0.983 -0.773 -1.108 -0.315
eps 0.96 -0.22 -3.6 2.16 -5.38 0.17 -14.85 -5.13 -5.15 -3.65 -4.47 -1.52 4.1 5.79
epsdiluted 0.91 -0.22 2.06 -5.38 0.17 -5.13 -5.15 -3.65 -1.52
weightedAverageShsOut 53M 54M 53M 53M 53M 52M 51M 52M 51M 50M 50M 50M 54M 53M
weightedAverageShsOutDil 57M 54M 53M 56M 53M 52M 51M 52M 51M 50M 50M 50M 54M 54M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-03-04 2024-03-08 2023-12-11 2022-02-25 2021-02-19
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -71M -88M -37M -35M -31M
ebit -52M -168M -109M 386M 499M
nonOperatingIncomeExcludingInterest -57M -558M -61M -45M -61M
netIncomeFromContinuingOperations -191M -761M -212M 220M 306M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 700 000
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -191M -761M -212M 220M 306M
epsDiluted -3.6 -14.85 -4.47 4.06 5.67

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-08-07 2024-11-07 2024-08-07 2024-03-31 2023-12-11 2023-08-09 2023-05-10 2022-11-09
acceptedDate 2025-10-29 17:38:45 2025-08-06 17:50:51 2025-03-03 17:41:27 2024-11-06 17:46:15 2024-08-06 17:37:18 2024-03-30 20:00:00 2024-03-08 16:21:44 2023-12-11 07:24:51 2023-08-08 18:42:41 2023-05-09 17:51:12 2023-12-11 07:17:14 2022-11-08 18:19:51 2022-02-25 16:35:23 2021-02-18 18:52:37
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 246M 271M 100M 150M 71M 79M 112M 88M 89M 430M 643M 241M 576M 621M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 246M 271M 100M 150M 71M 79M 112M 88M 89M 430M 643M 241M 576M 621M
netReceivables 150M 80M 155M 121M 196M 234M 191M 217M 290M 156M 159M 191M 279M 231M
inventory 356M 339M 312M 323M 318M 333M 329M 354M 354M 368M 351M 546M 345M 307M
otherCurrentAssets 36M 30M 33M 68M 71M 37M 48M 62M 45M 267M 58M 140M 70M 2M
totalCurrentAssets 787M 720M 599M 661M 655M 682M 680M 354M 778M 1 221M 1 210M 1 119M 1 270M 1 196M
propertyPlantEquipmentNet 210M 224M 271M 278M 320M 395M 399M 395M 396M 717M 837M 807M 828M 675M
goodwill 0 0 0 1 0 0 0 0 218M 218M 218M 225M 225M 267M
intangibleAssets 453M 469M 502M 518M 534M 550M 567M 583M 593M 609M 729M 723M 605M 663M
goodwillAndIntangibleAssets 453M 469M 502M 518M 534M 550M 567M 583M 811M 827M 947M 948M 830M 930M
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 12M 5M 19M 21M 5M 176M 178M 194M 195M 185M 172M 36M 30M 82M
totalNonCurrentAssets 674M 698M 791M 816M 859M 1 121M 1 144M 1 172M 1 401M 1 729M 1 956M 1 790M 1 688M 1 687M
otherAssets 0 0 0 0 0 1 0 367M 0 0 0 0 0 0
totalAssets 1 461M 1 417M 1 390M 1 478M 1 514M 1 804M 1 823M 1 893M 2 179M 2 950M 3 166M 2 909M 2 958M 2 883M
accountPayables 57M 64M 61M 82M 96M 100M 112M 113M 108M 124M 104M 104M 129M 136M
shortTermDebt 0 2M 3M 800 000 415M 463M 414M 414M 455M 951M 963M 21M 37M 40M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 5M 0 0 6M 6M 0 23M 101M 0 26M 0 12M 0
otherCurrentLiabilities 79M 57M 81M 147M 109M 62M 107M 115M 29M 141M 49M 143M 107M 72M
totalCurrentLiabilities 137M 127M 162M 230M 620M 630M 651M 664M 693M 1 216M 1 229M 268M 374M 385M
longTermDebt 663M 674M 664M 0 459M 447M 447M 448M 448M 448M 449M 1 032M 809M 850M
deferredRevenueNonCurrent 0 0 0 0 12M 13M 0 -448M 0 0 0 0 5M 0
deferredTaxLiabilitiesNonCurrent 36M 47M 42M 42M 35M 35M 0 52M 58M 60M 60M 114M 93M 0
otherNonCurrentLiabilities 43M 33M 29M 698M 14M 15M 76M 480M 23M 24M 27M 1 066M 41M 174M
totalNonCurrentLiabilities 742M 754M 745M 740M 508M 510M 523M 532M 529M 532M 550M 1 191M 972M 1 052M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 7M 10M 0 12M 13M 0 15M 13M 0 15M 0 24M 33M
totalLiabilities 879M 881M 907M 969M 1 127M 1 140M 1 174M 1 196M 1 223M 1 747M 1 779M 1 459M 1 346M 1 436M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000
retainedEarnings -105M -156M -212M -181M -296M -13M -22M 28M 290M 551M 739M 822M 950M 727M
accumulatedOtherComprehensiveIncomeLoss -8M -8M -5M -7M -6M -6M -6M -3M -2M 1 000 000 3M -5M -16M -25M
othertotalStockholdersEquity 695M 701M 697M 688M 682M 672M 668M 651M 632M
totalStockholdersEquity 583M 536M 483M 508M 386M 664M 649M 697M 956M 1 203M 1 388M 1 449M 1 612M 1 447M
totalEquity 583M 536M 483M 508M 386M 664M 649M 697M 956M 1 203M 1 388M 1 449M 1 612M 1 447M
totalLiabilitiesAndStockholdersEquity 1 461M 1 417M 1 478M 1 514M 1 804M 1 893M 2 179M 2 950M 2 909M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 461M 1 417M 1 390M 1 478M 1 514M 1 804M 1 823M 1 893M 2 179M 2 950M 3 166M 2 909M 2 958M 2 883M
totalInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalDebt 663M 676M 676M 800 000 877M 922M 860M 414M 903M 1 398M 1 426M 1 053M 871M 923M
netDebt 418M 405M 577M -149M 806M 843M 749M 326M 815M 968M 784M 812M 295M 302M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-03-04 2024-03-08 2023-12-11 2022-02-25 2021-02-19
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 135M 140M 159M 279M 231M
otherReceivables 20M 51M 0 0 0
prepaids 0 0 0 0 35M
totalPayables 61M 112M 104M 129M 136M
otherPayables 0 0 0 0 0
accruedExpenses 18M 19M 87M 89M 132M
capitalLeaseObligationsCurrent 0 0 0 0 5M
capitalLeaseObligationsNonCurrent 10M 0 15M 24M 28M
treasuryStock -228M -228M -228M -152M -40M
additionalPaidInCapital 928M 904M 874M 829M 785M
otherTotalStockholdersEquity 0 0 0 0 -1

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS EBS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-08-07 2024-11-07 2024-08-07 2024-03-31 2023-12-11 2023-08-09 2023-05-10 2022-11-09
acceptedDate 2025-10-29 17:38:45 2025-08-06 17:50:51 2025-03-03 17:41:27 2024-11-06 17:46:15 2024-08-06 17:37:18 2024-03-30 20:00:00 2024-03-08 16:21:44 2023-12-11 07:24:51 2023-08-08 18:42:41 2023-05-09 17:51:12 2023-12-11 07:17:14 2022-11-08 18:19:51 2022-02-25 16:35:23 2021-02-18 18:52:37
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 51M -12M -191M 115M -283M 9M -761M -263M -261M -183M -212M -76M 231M 306M
depreciationAndAmortization 23M 24M 109M 26M 29M 29M 125M 29M 33M 35M 143M 32M 124M 115M
deferredIncomeTax -10M -14M -6M 7M -200 000 -12M -9M 7M -2M -8M -29M 20M 47M -3M
stockBasedCompensation 5M 5M 18M 2M 6M 6M 23M 4M 8M 7M 45M 11M 42M 52M
changeInWorkingCapital -81M 96M 89M 66M 206M -98M -70M 65M -145M -37M -2M -75M -156M 10M
accountsReceivables -72M 119M -24M 82M 20M -50M -22M 72M -132M 2M 118M -22M -48M 28M
inventory -18M -25M -25M -18M -13M -5M 600 000 -1M 6M -30M -57M -37M -44M -67M
accountsPayables -4M -10M -33M -23M 3M -2M 11M 7M -20M 31M -14M -1M -3M 28M
otherWorkingCapital 12M 12M 171M 24M 196M -41M -60M -13M 2M -40M -49M -15M -62M 21M
otherNonCashItems 10M 9M 39M -63M 144M 124M 485M 219M 253M 3M 20M 13M 34M 59M
netCashProvidedByOperatingActivities -2M 106M 59M 154M 48M -63M -206M 60M -114M -184M -34M -74M 321M 537M
investmentsInPropertyPlantAndEquipment -3M -3M -23M -6M -5M -11M -52M -13M -13M -15M -116M -28M -225M -142M
acquisitionsNet 0 0 0 0 0 0 270M 0 270M 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 20M 118M 0 0 -6M 0 0 -244M
netCashUsedForInvestingActivites -3M 17M 112M -5M -11M -19M 258M -15M -272M
debtRepayment -7M 0 -194M -51M -41M -43M -496M -8M -8M
commonStockIssued 200 000 700 000 9M 700 000 0 0 10M 0 0
commonStockRepurchased -9M -7M 0 0 -200 000 -400 000 0 -100 000 -200 000 0 -82M 0 -106M 0
dividendsPaid 0 0 0 0 0 0 -9M 0 0
otherFinancingActivites -300 000 -200 000 4M 500 000 -400 000 -100 000 9M -2M 238M
netCashUsedProvidedByFinancingActivities -16M -6M -180M -51M 41M -43M -487M -11M 229M
effectOfForexChangesOnCash -200 000 1 000 000 0 0 0 0 -1M 1M -600 000 -200 000 500 000 -1 000 000 -300 000 -1 000 000
netChangeInCash -22M 118M -6M 85M -8M -33M -531M -91M -342M -212M 66M -117M -45M 454M
cashAtEndOfPeriod 249M 271M 106M 156M 71M 79M 112M -2M 89M 430M 643M 241M 576M 622M
cashAtBeginningOfPeriod 271M 153M 112M 71M 79M 112M 643M 89M 430M 643M 576M 358M 622M 168M
operatingCashFlow -2M 106M 59M 154M 48M -63M -206M 60M -114M -184M -34M -74M 321M 537M
capitalExpenditure -3M -3M -23M -6M -5M -11M -52M -13M -13M -15M -116M -28M -225M -142M
freeCashFlow -6M 104M 36M 148M 43M -73M -258M 47M -127M -199M -150M -102M 96M 395M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-03-04 2024-03-08 2023-12-11 2022-02-25 2021-02-19
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 148M -6M -266M 0 -10M
netCashProvidedByInvestingActivities 125M 212M -381M -225M -152M
netDebtIssuance -198M -543M 564M -36M 63M
longTermNetDebtIssuance -198M -543M 564M -36M 436M
shortTermNetDebtIssuance 0 0 0 0 -373M
netStockIssuance 9M 8M -82M -106M 0
netCommonStockIssuance 9M 8M -82M -106M 0
commonStockIssuance 9M 8M 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -900 000 -700 000 -900 000 900 000 7M
netCashProvidedByFinancingActivities -190M -536M 481M -141M 70M
incomeTaxesPaid 27M 53M 6M 72M 109M
interestPaid 64M 68M 33M 30M 21M

Earning call transcript

2025 q3
2025-10-29 ET (fiscal 2025 q3)
2025 q2
2025-08-07 ET (fiscal 2025 q2)
2025 q1
2025-05-07 ET (fiscal 2025 q1)
2024 q4
2025-03-03 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-01 ET (fiscal 2024 q1)
2023 q4
2024-03-06 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-27 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-01 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-28 20:01 ET
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
2026-05-20 11:30 ET
Emergent BioSolutions to Participate in Upcoming Investor Conferences
2026-05-18 12:59 ET
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
2026-04-30 ET
Emergent BioSolutions Reports First Quarter 2026 Financial Results
2026-04-30 ET
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
2026-04-29 ET
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
2026-04-29 ET
Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives
2026-04-28 ET
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
2026-04-16 ET
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
2026-04-16 ET
Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility
2026-04-09 ET
Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program
2026-04-07 ET
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
2026-04-02 ET
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
2026-03-25 ET
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
2026-03-03 ET
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
2026-02-26 ET
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-26 ET
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness
2026-02-26 ET
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
2026-02-12 23:00 ET
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
2026-02-12 14:02 ET
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
2026-01-14 ET
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness
2026-01-12 ET
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
2026-01-08 ET
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
2026-01-08 ET
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
2026-01-07 ET
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
2025-12-12 ET
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
2025-11-18 ET
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
2025-11-12 ET
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
2025-10-29 20:15 ET
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
2025-10-28 ET
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
2025-10-08 ET
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
2025-09-24 ET
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
2025-09-19 ET
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
2025-09-15 ET
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
2025-09-09 ET
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
2025-09-02 ET
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
2025-08-29 ET
Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
2025-08-27 ET
Emergent BioSolutions to Participate in Upcoming Investor Conferences
2025-08-21 ET
Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™
2025-08-06 ET
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
2025-07-28 ET
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
2025-07-28 ET
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
2025-07-15 ET
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
2025-07-08 ET
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
2025-07-02 ET
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
2025-06-23 ET
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
2025-06-20 ET
Emergent BioSolutions Announces Addition to Russell 3000® Index
2025-06-05 ET
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
2025-05-14 ET
Emergent BioSolutions to Participate in Upcoming Investor Conferences
2025-05-07 ET
Emergent BioSolutions Reports First Quarter 2025 Financial Results
2025-05-01 ET
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
2025-04-22 ET
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
2025-03-31 ET
Emergent BioSolutions Announces Stock Repurchase Program
2025-03-20 ET
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
2025-03-20 ET
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
2025-03-19 ET
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
2025-03-18 ET
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
2025-03-13 ET
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
2025-03-13 ET
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
2025-03-12 ET
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
2025-03-10 ET
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
2025-03-03 ET
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
2025-02-18 ET
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
2025-02-07 ET
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
2025-01-16 ET
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
2025-01-14 ET
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
2025-01-13 ET
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
2025-01-08 ET
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
2025-01-08 ET
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
2024-12-16 ET
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
2024-11-06 21:49 ET
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
2024-11-06 21:05 ET
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
2024-11-04 12:30 ET
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
2024-10-23 11:30 ET
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
2024-10-08 21:32 ET
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
2024-10-02 11:30 ET
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
2024-09-26 12:05 ET
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
2024-09-25 11:07 ET
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
2024-09-13 10:45 ET
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
2024-09-12 12:30 ET
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
2024-09-03 11:08 ET
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
2024-08-30 12:16 ET
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
2024-08-06 12:00 ET
Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
2024-07-31 12:53 ET
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
2024-07-24 11:30 ET
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
2024-07-23 12:27 ET
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
2024-07-09 11:30 ET
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
2024-07-02 12:13 ET
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
2024-06-20 11:00 ET
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
2024-06-06 13:02 ET
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
2024-05-10 11:17 ET
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
2024-05-01 20:57 ET
Emergent BioSolutions Reports First Quarter 2024 Financial Results
2024-05-01 20:10 ET
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
2024-05-01 15:03 ET
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
2024-04-30 21:26 ET
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
2024-04-22 12:05 ET
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
2024-03-28 12:15 ET
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
2024-03-25 12:05 ET
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
2024-03-06 21:31 ET
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
2024-02-29 12:00 ET
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
2024-02-21 12:00 ET
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
2024-01-11 13:00 ET
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
2024-01-11 ET
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
2024-01-09 12:30 ET
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
2023-11-28 11:59 ET
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
2023-11-28 ET
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
2023-11-24 12:30 ET
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
2023-11-08 22:38 ET
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
2023-10-30 20:45 ET
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
2023-10-30 ET
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
2023-10-19 10:30 ET
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
2023-10-16 11:00 ET
Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic
2023-10-02 11:00 ET
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
2023-08-30 09:59 ET
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
2023-08-08 20:31 ET
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
2023-08-08 11:15 ET
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
2023-07-31 20:05 ET
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
2023-07-25 10:30 ET
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
2023-07-20 22:03 ET
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
2023-06-27 11:55 ET
Emergent BioSolutions Announces CEO Transition
2023-05-15 11:58 ET
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
2023-05-15 11:58 ET
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
2023-05-11 10:30 ET
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
2023-05-09 20:05 ET
Emergent BioSolutions Reports Financial Results For First Quarter 2023
2023-04-19 20:05 ET
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
2023-03-29 13:48 ET
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
2023-02-27 21:42 ET
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
2023-02-15 22:19 ET
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
2023-02-15 07:00 ET
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
2023-02-15 07:00 ET
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
2023-02-06 21:05 ET
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
2023-01-09 11:59 ET
Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
2023-01-05 22:30 ET
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
2022-12-06 11:00 ET
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
2022-11-14 11:30 ET
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
2022-11-08 21:16 ET
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
2022-11-01 20:05 ET
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
2022-10-27 12:30 ET
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
2022-10-18 10:30 ET
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
2022-09-26 20:12 ET
Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
2022-09-06 10:30 ET
Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate
2022-08-10 10:30 ET
Emergent BioSolutions to Participate in Investor Conferences
2022-08-01 20:05 ET
Emergent BioSolutions Reports Financial Results for Second Quarter 2022
2022-07-18 20:05 ET
Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022
2022-07-07 20:30 ET
Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola
2022-07-06 20:05 ET
Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors
2022-06-24 10:30 ET
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
2022-06-21 10:30 ET
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
2022-06-02 12:20 ET
Emergent BioSolutions to Participate in Investor Conferences
2022-05-16 10:32 ET
Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
2022-05-12 10:30 ET
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
2022-05-10 20:42 ET
SHAREHOLDER ALERT: Weiss Law Investigates Emergent BioSolutions Inc.
2022-04-28 20:05 ET
Emergent BioSolutions Reports Financial Results For First Quarter 2022
2022-04-08 10:30 ET
Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
2022-03-23 20:05 ET
Emergent BioSolutions Provides Corporate Governance Update
2022-03-14 20:05 ET
Emergent BioSolutions to Participate in Investor Conferences
2022-03-11 11:34 ET
Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
2022-02-24 21:05 ET
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021
2022-02-07 11:30 ET
Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
2022-01-14 11:30 ET
Founder and Executive Chairman of Emergent BioSolutions Announces Retirement
2022-01-09 19:00 ET
Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
2022-01-03 11:30 ET
Emergent BioSolutions to Participate in Investor Conferences
2021-12-16 12:30 ET
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
2021-11-22 23:01 ET
SiTime Set to Join S&P MidCap 400; Emergent BioSolutions to Join S&P SmallCap 600
2021-11-11 21:05 ET
Emergent BioSolutions Announces Stock Repurchase Program
2021-11-04 20:05 ET
Emergent BioSolutions Reports Financial Results For Third Quarter 2021
2021-10-18 10:30 ET
Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021
2021-10-15 10:30 ET
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
2021-09-21 17:23 ET
Shuman, Glenn & Stecker Investigates Emergent BioSolutions, Inc.
2021-09-14 12:00 ET
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
2021-08-25 10:30 ET
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
2021-08-23 20:05 ET
Emergent BioSolutions to Participate in Investor Conferences
2021-07-29 20:05 ET
Emergent BioSolutions Reports Financial Results For Second Quarter 2021
2021-07-29 11:24 ET
Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
2021-07-26 13:01 ET
Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use
2021-07-15 10:30 ET
Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
2021-06-11 20:35 ET
COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
2021-05-26 10:30 ET
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
2021-05-06 10:30 ET
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT
2021-05-05 20:05 ET
Emergent BioSolutions to Participate in Investor Conferences
2021-04-29 20:05 ET
Emergent BioSolutions Reports Financial Results for First Quarter 2021
2021-04-21 16:46 ET
Statement on Issuance of Form FDA 483 at Emergent Bayview Facility
2021-04-15 10:30 ET
Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021
2021-04-08 15:51 ET
Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS)
2021-04-02 12:00 ET
Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19
2021-03-01 11:30 ET
Emergent BioSolutions to Participate in Investor Conferences
2021-02-18 21:05 ET
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
2021-02-04 11:30 ET
Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021
2021-01-10 19:00 ET
Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results
2021-01-04 11:30 ET
Emergent BioSolutions to Participate in Investor Conferences
2020-12-29 21:05 ET
Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis
2020-11-05 21:05 ET
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance
2020-10-15 10:30 ET
Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020
2020-10-08 20:05 ET
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19
2020-08-31 10:30 ET
Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day
2020-08-26 10:30 ET
Emergent BioSolutions Announces Appointment of Marvin White to the Company’s Board of Directors
2020-08-18 10:31 ET
Emergent BioSolutions to Participate in Virtual Investor Conferences
2020-08-17 10:30 ET
Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
2020-08-07 20:05 ET
Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028
2020-08-04 22:31 ET
Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028
2020-08-04 12:00 ET
Emergent BioSolutions Announces Proposed Offering of $400 Million of Senior Unsecured Notes
2020-07-30 20:27 ET
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance
2020-07-27 10:30 ET
Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate
2020-07-21 20:45 ET
Emergent BioSolutions Inc. to be Added to the S&P MidCap 400 Index
2020-07-20 22:36 ET
Emergent BioSolutions Set to Join S&P MidCap 400; First Hawaiian to Join S&P SmallCap 600
2020-07-16 10:30 ET
Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020
2020-07-08 13:00 ET
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding
2020-07-06 10:30 ET
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate   
2020-06-18 10:30 ET
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
2020-06-16 20:05 ET
Emergent BioSolutions to Participate in Virtual Investor Conferences
2020-06-11 12:47 ET
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate
2020-06-05 23:39 ET
Emergent BioSolutions Statement on U.S. District Court Decision
2020-06-01 10:30 ET
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
2020-05-12 10:00 ET
Emergent BioSolutions to Participate in Virtual Investor Conferences
2020-05-07 13:20 ET
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 21, 2020 at 9:00am EDT
2020-04-30 20:08 ET
Emergent BioSolutions Reports Financial Results for First Quarter 2020
2020-04-23 22:51 ET
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
2020-04-21 20:55 ET
Emergent BioSolutions Appoints Dr. Karen L. Smith as Chief Medical Officer
2020-04-16 10:30 ET
Emergent BioSolutions to Release First Quarter 2020 Financial Results and Conduct Conference Call on April 30, 2020
2020-04-06 10:30 ET
Emergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs
2020-04-02 20:05 ET
Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19
2020-03-31 20:05 ET
Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™
2020-03-18 10:30 ET
EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE
2020-03-11 20:21 ET
Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease
2020-03-10 09:30 ET
Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease
2020-02-20 21:31 ET
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2019
2020-02-03 21:30 ET
Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020
2020-01-31 14:26 ET
Emergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency
2020-01-13 11:40 ET
Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
2020-01-13 11:30 ET
Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast
2020-01-06 11:30 ET
Emergent BioSolutions to Participate in Investor Conferences
2019-12-20 18:00 ET
Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors
2019-11-22 13:19 ET
Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate
2019-11-21 21:05 ET
Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day
2019-11-18 11:30 ET
Emergent BioSolutions to Host 2019 Analyst and Investor Day
2019-11-06 21:05 ET
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019
2019-04-18 11:22 ET
Emergent BioSolutions to Release First Quarter 2019 Financial Results and Conduct a Conference Call on May 2, 2019
2019-04-16 10:30 ET
Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate
2019-03-19 10:30 ET
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax

SEC forms

Show financial reports only

SEC form 8
2026-02-26 16:08 ET
Emergent BioSolutions published news for 2025 q4
SEC form 8
2026-02-26 16:08 ET
Emergent BioSolutions reported for 2025 q4
SEC form 8
2026-02-26 16:08 ET
Emergent BioSolutions published news for 2025 q4
SEC form 8
2025-10-29 20:19 ET
Emergent BioSolutions published news for 2025 q3
SEC form 8
2025-10-29 20:19 ET
Emergent BioSolutions reported for 2025 q3
SEC form 8
2025-10-29 20:19 ET
Emergent BioSolutions published news for 2025 q3
SEC form 10
2025-08-06 21:50 ET
Emergent BioSolutions reported for 2025 q2
SEC form 8
2025-08-06 20:13 ET
Emergent BioSolutions published news for 2025 q2
SEC form 8
2025-08-06 20:13 ET
Emergent BioSolutions reported for 2025 q2
SEC form 8
2025-08-06 20:13 ET
Emergent BioSolutions published news for 2025 q2
SEC form 8
2025-06-24 20:09 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-06-24 20:09 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-05-23 20:06 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-05-23 20:06 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-05-23 20:06 ET
Emergent BioSolutions published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Emergent BioSolutions published news for 2025 q1
SEC form 10
2025-05-07 21:46 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-05-07 20:08 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-05-07 20:08 ET
Emergent BioSolutions reported for 2025 q1
SEC form 8
2025-05-07 20:08 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-05-06 20:19 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-03-31 12:06 ET
Emergent BioSolutions published news for 2024 q4
SEC form 8
2025-03-31 12:06 ET
Emergent BioSolutions published news for 2024 q4
SEC form 8
2025-03-10 20:47 ET
Emergent BioSolutions published news for 2024 q4
SEC form 8
2025-03-10 20:47 ET
Emergent BioSolutions published news for 2024 q4
SEC form 10
2025-03-04 00:00 ET
Emergent BioSolutions published news for 2024 q4
SEC form 10
2025-03-03 22:41 ET
Emergent BioSolutions published news for 2024 q4
SEC form 8
2025-03-03 16:27 ET
Emergent BioSolutions published news for 2024 q4
SEC form 8
2025-03-03 16:27 ET
Emergent BioSolutions reported for 2024 q4
SEC form 8
2025-03-03 16:27 ET
Emergent BioSolutions published news for 2024 q4
SEC form 10
2024-11-06 17:46 ET
Emergent BioSolutions published news for 2024 q3
SEC form 8
2024-11-06 16:12 ET
Emergent BioSolutions published news for 2024 q3
SEC form 8
2024-11-06 16:12 ET
Emergent BioSolutions published news for 2024 q3
SEC form 8
2024-11-06 16:12 ET
Emergent BioSolutions published news for 2024 q3
SEC form 10
2024-08-07 00:00 ET
Emergent BioSolutions published news for 2024 q2
SEC form 10
2024-08-06 17:37 ET
Emergent BioSolutions published news for 2024 q2
SEC form 8
2024-08-06 16:21 ET
Emergent BioSolutions published news for 2024 q2
SEC form 8
2024-08-06 16:21 ET
Emergent BioSolutions reported for 2024 q2
SEC form 8
2024-08-06 16:21 ET
Emergent BioSolutions published news for 2024 q2
SEC form 10
2024-05-02 00:00 ET
Emergent BioSolutions published news for 2024 q1
SEC form 10
2024-05-01 17:38 ET
Emergent BioSolutions published news for 2024 q1
SEC form 10
2024-03-08 16:21 ET
Emergent BioSolutions published news for 2023 q4
SEC form 10
2024-03-08 00:00 ET
Emergent BioSolutions reported for 2023 q4
SEC form 10
2023-12-11 00:00 ET
Emergent BioSolutions published news for 2023 q3
SEC form 8
2023-11-08 16:21 ET
Emergent BioSolutions reported for 2023 q3
SEC form 10
2023-08-09 00:00 ET
Emergent BioSolutions reported for 2023 q2
SEC form 10
2023-08-08 18:42 ET
Emergent BioSolutions published news for 2023 q2
SEC form 6
2023-08-08 16:12 ET
Emergent BioSolutions reported for 2023 q2
SEC form 6
2023-08-08 07:15 ET
Emergent BioSolutions published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Emergent BioSolutions published news for 2023 q2
SEC form 6
2023-07-31 16:26 ET
Emergent BioSolutions published news for 2023 q2
SEC form 6
2023-07-27 16:48 ET
Emergent BioSolutions published news for 2023 q2
SEC form 6
2023-07-21 08:25 ET
Emergent BioSolutions published news for 2023 q2
SEC form 6
2023-06-27 07:54 ET
Emergent BioSolutions published news for 2023 q1
SEC form 6
2023-05-31 17:00 ET
Emergent BioSolutions published news for 2023 q1
SEC form 6
2023-05-30 07:32 ET
Emergent BioSolutions published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Emergent BioSolutions published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Emergent BioSolutions reported for 2023 q1
SEC form 6
2023-04-17 07:46 ET
Emergent BioSolutions published news for 2023 q1
SEC form 6
2023-03-29 09:29 ET
Emergent BioSolutions published news for 2022 q4
SEC form 6
2023-03-23 17:25 ET
Emergent BioSolutions published news for 2022 q4
SEC form 10
2023-03-01 16:18 ET
Emergent BioSolutions reported for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Emergent BioSolutions reported for 2022 q4
SEC form 6
2023-02-27 16:46 ET
Emergent BioSolutions published news for 2022 q4
SEC form 8
2023-02-27 00:00 ET
Emergent BioSolutions reported for 2022 q4
SEC form 6
2023-02-15 07:06 ET
Emergent BioSolutions published news for 2022 q4
SEC form 6
2023-01-09 06:55 ET
Emergent BioSolutions published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Emergent BioSolutions published news for 2022 q4
SEC form 6
2023-01-05 17:27 ET
Emergent BioSolutions published news for 2022 q4
SEC form 6
2022-12-06 07:01 ET
Emergent BioSolutions published news for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Emergent BioSolutions reported for 2022 q3
SEC form 10
2022-11-08 18:19 ET
Emergent BioSolutions published news for 2022 q3
SEC form 6
2022-11-08 16:52 ET
Emergent BioSolutions published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Emergent BioSolutions reported for 2022 q3
SEC form 6
2022-09-26 17:05 ET
Emergent BioSolutions published news for 2022 q2
SEC form 6
2022-08-12 17:03 ET
Emergent BioSolutions published news for 2022 q2
SEC form 6
2022-08-02 18:19 ET
Emergent BioSolutions published news for 2022 q2
SEC form 10
2022-08-02 00:00 ET
Emergent BioSolutions reported for 2022 q2
SEC form 10
2022-08-01 18:02 ET
Emergent BioSolutions published news for 2022 q2
SEC form 6
2022-08-01 16:11 ET
Emergent BioSolutions published news for 2022 q2
SEC form 8
2022-08-01 00:00 ET
Emergent BioSolutions reported for 2022 q2
SEC form 6
2022-07-06 16:09 ET
Emergent BioSolutions published news for 2022 q2
SEC form 6
2022-06-07 06:43 ET
Emergent BioSolutions published news for 2022 q1
SEC form 6
2022-06-06 08:03 ET
Emergent BioSolutions published news for 2022 q1
SEC form 6
2022-05-27 08:29 ET
Emergent BioSolutions published news for 2022 q1
SEC form 6
2022-05-18 17:13 ET
Emergent BioSolutions published news for 2022 q1
SEC form 6
2022-05-16 06:49 ET
Emergent BioSolutions published news for 2022 q1
SEC form 10
2022-04-29 00:00 ET
Emergent BioSolutions reported for 2022 q1
SEC form 10
2022-04-28 17:44 ET
Emergent BioSolutions published news for 2022 q1
SEC form 6
2022-04-28 16:45 ET
Emergent BioSolutions published news for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Emergent BioSolutions reported for 2022 q1
SEC form 6
2022-04-15 16:51 ET
Emergent BioSolutions published news for 2022 q1
SEC form 6
2022-03-23 16:30 ET
Emergent BioSolutions published news for 2021 q4
SEC form 10
2022-02-25 16:35 ET
Emergent BioSolutions published news for 2021 q4
SEC form 10
2022-02-25 00:00 ET
Emergent BioSolutions published news for 2021 q4
SEC form 6
2022-02-24 16:22 ET
Emergent BioSolutions published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Emergent BioSolutions published news for 2021 q4
SEC form 6
2022-02-22 16:11 ET
Emergent BioSolutions published news for 2021 q4
SEC form 6
2022-01-14 06:37 ET
Emergent BioSolutions published news for 2021 q4
SEC form 6
2022-01-10 06:09 ET
Emergent BioSolutions published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Emergent BioSolutions published news for 2021 q4
SEC form 6
2021-11-12 08:48 ET
Emergent BioSolutions published news for 2021 q3
SEC form 10
2021-11-05 16:51 ET
Emergent BioSolutions published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
Emergent BioSolutions published news for 2021 q3
SEC form 6
2021-11-04 16:19 ET
Emergent BioSolutions published news for 2021 q3
SEC form 6
2021-11-04 16:13 ET
Emergent BioSolutions published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Emergent BioSolutions published news for 2021 q3
SEC form 6
2021-09-30 20:14 ET
Emergent BioSolutions published news for 2021 q2
SEC form 6
2021-09-09 16:33 ET
Emergent BioSolutions published news for 2021 q2
SEC form 10
2021-07-30 00:00 ET
Emergent BioSolutions published news for 2021 q2
SEC form 10
2021-07-29 19:08 ET
Emergent BioSolutions published news for 2021 q2
SEC form 6
2021-07-29 16:26 ET
Emergent BioSolutions published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Emergent BioSolutions published news for 2021 q2
SEC form 6
2021-07-22 16:50 ET
Emergent BioSolutions published news for 2021 q2
SEC form 6
2021-07-14 06:27 ET
Emergent BioSolutions published news for 2021 q2
SEC form 6
2021-05-25 16:59 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-05-12 08:30 ET
Emergent BioSolutions published news for 2021 q1
SEC form 10
2021-04-30 00:00 ET
Emergent BioSolutions published news for 2021 q1
SEC form 10
2021-04-29 18:01 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-04-29 16:24 ET
Emergent BioSolutions published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-04-21 13:27 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-04-19 06:20 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-04-09 16:04 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-04-05 07:38 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-04-01 17:01 ET
Emergent BioSolutions published news for 2021 q1
SEC form 10
2021-02-18 18:52 ET
Emergent BioSolutions published news for 2020 q4
SEC form 6
2021-02-18 16:46 ET
Emergent BioSolutions published news for 2020 q4
SEC form 6
2021-02-16 16:46 ET
Emergent BioSolutions published news for 2020 q4
SEC form 6
2021-01-11 06:34 ET
Emergent BioSolutions published news for 2020 q4
SEC form 10
2020-11-05 18:54 ET
Emergent BioSolutions published news for 2020 q3
SEC form 6
2020-11-05 16:43 ET
Emergent BioSolutions published news for 2020 q3